Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P240021/S001

Atellica IM Total PSA II (tPSAII)

Siemens Healthcare Diagnostics, Inc. · Decision date Aug 26, 2026

FDA DECISIONP240021/S001

What did the FDA approve?

FDA records P240021/S001 as a supplement to PMA P240021, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Aug 26, 2026.

FDA approval order statement

Approval for the Atellica IM total PSA II (tPSAII):The Atellica IM total PSA II (tPSAII) assay is for in vitro diagnostic use in the quantitative measurement of total prostate-specific antigen (PSA) in human serum and plasma (EDTA and lithium-heparin) using the Atellica CI Analyzer. This assay is indicated as an aid in the detection of prostate cancer in conjunction with a digital rectal exam (DRE) in men aged 50 years and older. A prostate biopsy is required for the diagnosis of prostate cancer.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Immunology
Decision date
Aug 26, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P240021/S001
Regulatory pathway
PMA supplement
Product code
MTF
Decision code
APPR
Decision date
Aug 26, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer.

Product code
MTF
FDA device class
3

For the original device and its historical approval scope, see PMA P240021. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P240021 · Original PMA

    Atellica IM Total PSA II (tPSAII)

  2. P240021/S001 received

    Application receipt date recorded by FDA.

  3. P240021/S001 · FDA decision

    Normal 180 Day Track

Timeline entries are records held by MedtechLedger for P240021. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240021

Product / regulatory recordCompanyPathwayDecision dateSource
Siemens Healthcare Diagnostics, Inc.PMA approvalDec 3, 2025FDA

Explore the linked device profile

Other records with product code MTF

Product / regulatory recordCompanyPathwayDecision dateSource
Siemens Healthcare Diagnostics, Inc.PMA supplementSep 22, 2026FDA
Siemens Healthcare Diagnostics, Inc.PMA supplementAug 20, 2026FDA
IMMULITE 2000 PSAP930027/S039
Siemens Healthcare Diagnostics, Inc.PMA supplementJul 27, 2026FDA
Roche Diagnostics Corp.PMA supplementApr 29, 2026FDA
IMMULITE 2000 PSAP930027/S038
Siemens Healthcare Diagnostics, Inc.PMA supplementApr 21, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Siemens Healthcare Diagnostics, Inc.

Headquarters
Not reported
FDA applicant address
511 Benedict Ave., Tarrytown, NY, 10591

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records